
    
      A Global, Single Arm, Phase 2 Study of ARX788 in HER2-positive, Metastatic Breast Cancer
      Patients whose disease is Resistant or Refractory to T-DM1, and/or T-DXd, and/or
      Tucatinib-containing Regimens. The ARX788 will be administered every 4 weeks (Q4W)
      intravenous (IV) infusion.
    
  